Through complementary application of SNP genotyping, whole-genome sequencing and imputation in 38,384 Icelanders, we have discovered a previously unidentified sick sinus syndrome susceptibility gene, MYH6, encoding the alpha heavy chain subunit of cardiac myosin. A missense variant in this gene, c.2161C>T, results in the conceptual amino acid substitution p.Arg721Trp, has an allelic frequency of 0.38% in Icelanders and associates with sick sinus syndrome with an odds ratio = 12.53 and P = 1.5 × 10 −29 . We show that the lifetime risk of being diagnosed with sick sinus syndrome is around 6% for non-carriers of c.2161C>T but is approximately 50% for carriers of the c.2161C>T variant.
A r t i c l e s
Sick sinus syndrome (SSS), or sinus node dysfunction, is a common clinical disorder first described in 1968 (ref. 1) that is characterized by pathological sinus bradycardia (slow heart rate), sinus arrest and/or chronotropic incompetence (attenuated heart rate response to exercise). The syndrome comprises a wide range of electrophysiological abnormalities, including failure of the sinus node and atrial impulse formation or propagation, as well as susceptibility to atrial tachyarrhythmias, particularly atrial fibrillation 2 . Although encountered at any age, SSS is primarily a disease of the elderly and is often secondary to other cardiac disorders when diagnosed in younger individuals. Symptoms are often intermittent and/or nonspecific and include dizziness, syncope and heart failure. The only effective treatment for symptomatic and irreversible sinus node dysfunction is permanent cardiac pacing 3 , and SSS remains the most common indication for permanent pacemaker implantation 4 .
Several studies have uncovered gene mutations in sporadic cases and kindreds with familial SSS, both with and without other concomitant cardiac conditions, mainly through candidate gene approaches. Implicated genes have been ion channel or ion channel-associated genes, including SCN5A (ref. 5) , HCN4 (refs. 6,7) and ANK2 (ref. 8) . Similarly, knockout mouse models of various ion-channel and gapjunction subunits have been shown to result in the SSS phenotype 9 .
With the aim of searching for sequence variants that predispose to SSS, we performed a genome-wide association study (GWAS) on 792 Icelandic individuals with SSS and 37,592 Icelandic population controls (Supplementary Table 1 ). All cases had received a diagnosis of SSS at Landspitali University Hospital (LUH) in Reykjavik, Iceland, the only tertiary care hospital in Iceland. Of the 792 SSS cases, 627 had undergone pacemaker implantation.
Initially, we tested a total of 7.2 million SNPs either directly genotyped with the Illumina HumanHap300 or CNV370 chips or imputed from one or more of four sources: the HapMap2 European CEU sample 10 (60 triads), the 1000 Genomes Project data 11 (179 individuals) and Icelandic samples genotyped with the Illumina Human1M-Duo (123 triads) or the HumanOmni1-Quad chips (505 individuals). Imputations were based on the IMPUTE model 12 and long range phasing of chip-typed Icelandic samples 13 .
RESULTS

A rare missense variant in MYH6 associates with SSS
The genome-wide association analysis yielded significant association between SSS and three correlated SNPs at chromosome 14q11 (between 22.40 Mb and 22.94 Mb in build 36; Supplementary Table 2) : rs2231801 (imputed from the Human1M-Duo and HumanOmni1-Quad chips), rs28730774 (imputed from the HumanOmni1-Quad chip) and 14-22399934 (imputed from the 1000 Genomes Project) (most significant P = 1.3 × 10 −13 for rs2231801). For all three SNPs, A rare variant in MYH6 is associated with high risk of sick sinus syndrome the association of c.2161C>T could not be accounted for by any other genotyped or imputed variant.
In order to validate the c.2161C>T mutation and to explore its relationship with rs28730774[T], we used Sanger sequencing to resequence exon 18 of MYH6 in a set of 351 Icelanders (118 SSS cases and 233 controls) enriched for carriers of rs28730774 [T] . We also genotyped the mutation directly with a Centaurus single SNP assay in the same sample set, and the two genotyping methods concurred for all 351 individuals. In this set, 82 individuals were called as heterozygous carriers of c.2161C>T and none was called as homozygous. To increase imputation accuracy, we subsequently genotyped an additional 523 chip-typed Icelanders, primarily controls (50 SSS cases and 473 controls), with the c.2161C>T Centaurus assay. Four of these individuals were called as heterozygous carriers for c.2161C>T. Amongst the two sample sets combined, there were 130 carriers of rs28730774 [T] . The c.2161C>T variant was only observed amongst carriers of rs28730774 [T] and was found in 91% of SSS case carriers but only in 38% of control carriers (P = 2.9 × 10 −9 ; Supplementary Table 6) .
We combined the 87 whole-genome sequenced samples and the 874 Centaurus single-SNP assay and chip-genotyped individuals into a set of 952 individuals (five individuals overlapped and nine could not be phased accurately in the region around MYH6), of which 73 were carriers of the c.2161C>T mutation, to create a new reference set for imputation. Based on this imputation set, the association was stronger than when it was based on the initial imputation set. The c.2161C>T missense mutation in MYH6 resulting in p.Arg721Trp (estimated allelic frequency in Iceland = 0.38%) associates with SSS with an odds ratio (OR) = 12.53 (95% CI 8.08-19.44) and a corresponding P = 1.5 × 10 −29 .
We genotyped c.2161C>T in a second set of 469 Icelandic SSS cases and 1,185 controls who were not chip-genotyped and therefore unavailable for the haplotype-based imputation of c.2161C>T (Supplementary Tables 1,7) . Among the SSS cases, we identified 20 heterozygous carriers of c.2161C>T (allelic frequency of 2.1%), whereas the imputed minor allele frequency was low (0.010-0.026), and the minor allele was the risk allele.
In an effort to search for additional signals associating with SSS and to explore the observed association at 14q11, we selected seven chiptyped SSS cases for whole-genome sequencing, four of whom carried the rs28730774[T] variant (Fig. 1) . The selection was based on this variant rather than rs2231801 because its association with SSS was stronger in the imputations based on the HumanOmni1-Quad chips where both SNPs were genotyped (Supplementary Table 2 ). We also whole-genome sequenced another 80 chip-typed Icelanders not diagnosed with SSS (see Online Methods for selection criteria) for a total of 87 samples that we sequenced to a mean mapped sequencing depth of 10× (Supplementary Fig. 1 ). Based on these sequencing data, a total of ~11 million SNPs were called and imputed into chip-typed cases and controls, applying the long range phased haplotypes, and tested for association with SSS (See Supplementary Table 3 for exact SNP count and overlap with SNPs from the 1000 Genomes Project and dbSNP, Supplementary Table 4 for rediscovery rates of SNPs on the 300K Illumina chips and Supplementary Table 5 for whole-genome sequencing depth and chip genotype comparison per sample). We found no significant association outside the 14q11 region. In this region, the strongest association observed was with a missense mutation, c.2161C>T, in MYH6, a gene encoding the alpha heavy chain subunit of cardiac myosin (Fig. 2 , and see Supplementary Fig. 2 for the sequencing depth over the 14q11 region). This mutation was present in all four sequenced SSS rs28730774[T] carrier cases but was absent from both the non-carrier cases and a single control carrier of rs28730774 [T] . The c.2161C>T mutation is located in exon 18 of MYH6 at position 22,936,019 bp (in build 36 assembly of the UCSC Genome Browser) and leads to a missense arginine to tryptophan alteration at amino acid 721, p.Arg721Trp. No significant association remained at 14q11 after accounting for the effect of c.2161C>T, and The sibling recurrence risk ratio (λ sibling ) is a commonly used measure of the strength of familial aggregation. Based on the allelic frequency of c.2161C>T of 0.38% and an OR for SSS of 12.53, we estimated the λ sibling for SSS accounted for by c.2161C>T to be 1.52. This contrasts with most of the sequence variants that in recent years have been found to associate with common complex disorders and create λ sibling values that that are substantially less than 1.1. Despite the high OR, the c.2161C>T mutation is also distinct from most Mendelian disorder alterations because of its higher population frequency. There is, however, a striking similarity with the Icelandic c.999del5 BRCA2 breast cancer mutation 14 , which is almost exclusive to Iceland and which we estimate to have an allelic frequency of 0.43% (based on 20,635 males) and an OR of 11.4 (based on 2,466 female cases and 25,357 female controls) leading to a λ sibling of 1.47.
The 73 chip-typed individuals who were shown to carry the c.2161C>T mutation through direct genotyping all share a 26-SNP haplotype spanning 230 kb, or 0.51 cM. Using surrounding SNPs, we estimated the age of the introduction of the c.2161C>T mutation to Iceland, either by mutation or by immigration, to be 29 generations, or approximately 870 years 15, 16 .
Carriers of c.2161C>T have a high lifetime risk of SSS
Based on data from the 38,384 chip-typed Icelanders, including both SSS cases and controls, the lifetime risk of being diagnosed with SSS is ~6% for non-carriers of c.2161C>T but is ~50% for carriers of the c.2161C>T mutation (Fig. 3) . Notably, the chiptyped Icelanders were not selected for genotyping based on SSS or any other phenotype related to SSS and can therefore be used to assess the probability of developing SSS depending on genotype and age. The effect of c.2161C>T as estimated by our logistic model shows a trend toward increasing with age by a factor of 1.06 per 10 years (P = 0.042). We note that the cases and controls in our study are not age matched but that the frequency of c.2161C>T is independent of year of birth (Supplementary Fig. 3 ; correlation r= -0.0043, P = 0.41).
To explore the relationship between SSS, genotype and syncope, a common but nonspecific sign of SSS, we obtained a list of individuals who had received the discharge diagnosis of syncope (syncope, convulsions or dizziness; Online Methods) at the LUH between the years 1987 and 2010 either through a visit to the emergency room or hospital admission. For our analysis, we used data from the 916 individuals who had previously been chip-typed at deCODE (mean year of birth = 1929.7). We observed that amongst individuals with syncope, 50% of carriers (N = 16) of the c.2161C>T mutation had been diagnosed with SSS compared to 19% of the non-carriers (N = 900, P = 0.0050).
Association with heart rate
Although MYH6 has not previously been associated with SSS or other arrhythmias in man, we recently established a link between a common variant in this gene and cardiac conduction. Through a large GWAS on electrocardiogram (ECG) measures in Icelanders 17 , we discovered an association between a missense variant in exon 25 of MYH6 (rs365990[G], p.Ala1101Val) and both heart rate and the PR interval. The G allele of rs365990 (frequency = 0.341) associates with a 0.91-beat decrease in heart rate per minute. The association between rs365990[G] and heart rate has since been replicated in a large meta-analysis including subjects of European ancestry from both the United States and Europe 18 . There is, however, not a significant association between this variant and SSS in our data. The c.2161C>T mutation occurs on the background of the G allele of rs365990, and when tested in our previously described ECG database 17 (Supplementary Table 8) , after exclusion of all cases with SSS and pacemakers, we found it to associate with a 4.16-beat decrease in heart rate per minute (P = 0.0019) and a prolongation of the PR interval ( Table 1) . The association of c.2161C>T with lower heart rate in subjects who have not been diagnosed with SSS indicates a higher penetration of this mutation than suggested by purely assessing the association with the diagnosis of SSS but with variation in expressivity.
Correlation between c.2161C>T and other cardiac diseases
Given the fact that SSS is commonly associated with other cardiac diseases, particularly other conduction disorders, we tested for association between the c.2161C>T variant and several other cardiovascular diseases ( Table 2) . We analyzed Icelandic sample sets both before and after exclusion of known cases of SSS. Although these results can only be considered as suggestive, there was a residual association, after exclusion of SSS cases, with several diseases, including atrial fibrillation and thoracic aortic aneurysm.
DISCUSSION
Cardiac muscle myosin, along with actin, is one of the major components of the sarcomere, the building block of the contractile system of cardiac muscle 19 . Myosin is a hexamer consisting of two heavy chain subunits (alpha and beta), two light chain subunits and two regulatory subunits. MYH6 encodes the alpha myosin heavy chain subunit (αMHC) that encompasses ~26,000 bp and consists of 39 exons, 37 of which contain coding information 20 ( Supplementary Fig. 4) . The beta myosin heavy chain subunit (βMHC), a relatively slow ATPase encoded by MYH7, is the heavy chain isoform predominantly expressed in human heart, with expression of αMHC, a fast ATPase, being primarily restricted to atrial tissue 21 . The two genes (MYH6 and MYH7) are in a head-to-tail orientation on chromosome 14 22 and are regulated in an antithecal manner. In heart failure and other cardiac disorders in humans, βMHC is upregulated, whereas αMHC is downregulated, resulting in diminution of cardiac performance 23 , and it has been suggested that even minor shifts in the MHC composition of the cardiac muscle can markedly influence cardiac function. Mutations in MYH7 are a well-known cause of hypertrophic cardiomyopathy in man, and recently, mutations in MYH6 were also linked to both cardiomyopathy (hypertrophic and dilated) 24 and a variety of congenital heart defects 25 . The mutation resulting in p.Arg721Trp is in exon 18 that encodes part of the converter domain of αMHC (Supplementary Fig. 4 ). This domain functions as a socket for the C-terminal α-helical tail of the αMHC and plays a critical role in amplifying the structural rearrangements in the motor domain and transmitting them to the α-helical tail during movements of the myosin during contraction 26 . Based on PolyPhen 27 , the p.Arg721Trp alteration is predicted to alter the structure of the converter. Whether and how this structural alteration may directly affect cardiac conduction is pending further structurefunction analysis of the protein. Further, although the αMHC itself has not been directly linked to cardiac conduction, a cardiac-specific highly conserved microRNA, miR-208a, encoded by intron 27 of MYH6 in both humans and mice, has recently been shown in mice to be necessary for maintenance of normal cardiac conduction 27 . Evidence suggests that miR-208a is required for expression of Gja5 (also known as Cx40), which is of particular interest as mice lacking Gja5 show cardiac conduction abnormalities, including both sinus node impulse formation and atrial propagation [28] [29] [30] . Thus, another potential functional consequence of the p.Arg721Trp alteration could be an effect on αMHC mRNA stability or processing, as previously documented for both synonymous and nonsynonymous coding mutations [30] [31] [32] , which would directly affect the amount of miR-208a present in the heart. In summary, we have discovered a rare variant in a previously unidentified SSS susceptibility gene that confers high risk of the disease. The same variant has a substantial effect on heart rate in subjects who have not been diagnosed with SSS. We have shown that common variants in this gene modulate cardiac conduction affecting heart rate and the PR interval. To the best of our knowledge, this was the first time that cardiac myosin, a key component of the cardiac contractile system, was directly linked to cardiac conduction in humans. We have now established the importance of cardiac myosin in the development of cardiac arrhythmias.
In the last few years, GWAS have proven highly effective in unraveling the genetic architecture of complex human traits, yielding robust associations with hundreds of genomic variants. By design, the GWAS methods capture a large fraction of the common variants in the human genome. However, it has become apparent that despite expanded GWAS that capture common variants with both moderate and small effects, a substantial fraction of the heritability of most traits remains unaccounted for. The question has thus been raised of whether uncommon variants with substantial or large effects contribute to the genetic component of complex traits. This possibility is supported by a recent study of hypertriglyceridemia, in which resequencing of four genes associated with the trait through GWAS suggested an interplay between common and rare variants in the genetic architecture of this specific phenotype 33 . Through complementary application of SNP genotyping, whole-genome sequencing and imputation in the study of SSS, we now provide further evidence for the role of rare variants in the development of common complex diseases. either through a visit to the emergency room or hospital admission. Other samples have been described elsewhere 17, 34 . The controls used in the various case-control analyses of this study consisted of disease-free controls randomly drawn from the Icelandic genealogical database and individuals from other genetic studies at deCODE.
Non-Icelandic samples. The Danish 35 and Dutch 36 samples used to search for the presence of the c.2161C>T mutation have been previously described. The US SSS cases and controls come from the Vanderbilt atrial fibrillation registry, also previously described 37 .
Illumina genome-wide genotyping. The Icelandic chip-typed samples were assayed with the Illumina HumanHap300 or HumanHap CNV370 bead chips at deCODE genetics. The bead chips contained 317,503 and 370,404 haplotype tagging SNPs derived from phase I of the International HapMap Project. Only SNPs present on both chips were included in the analysis, and SNPs were excluded if they had (i) yield lower than 95% in cases or controls, (ii) minor allele frequency less than 1% in the population or (iii) significant deviation from Hardy-Weinberg equilibrium in the controls (P < 0.001). All samples with a call rate below 98% were excluded from the analysis. The final set of SNPs used for phasing was composed of 289,658 directly genotyped autosomal SNPs.
Sanger sequencing. Dye-terminator Sanger sequencing was performed with the Applied Biosystems BigDye Terminator v3.1 Cycle Sequencing Kit with Agencourt Ampure XP and Agencourt CleanSeq for cleanup of the PCR and cycle sequencing product, respectively. AmpureXP and CleanSeq bead cleaning was performed on Zymark Sciclone ALH-500 liquid handling robot system. Tray dilutions for PCR setup and cycle sequencing setup were prepared on Packard MultiprobeII HTEX liquid handling robot system, and the genomic DNA and PCR product were transferred into the respective trays using Zymark Sciclone ALH-500. PCR and cycle sequencing reactions were performed on MJ Research PTC-225 thermal cyclers. For signal detection, Applied Biosystems 3730xl DNA analyzers were used.
Single SNP genotyping. Single SNP genotyping was carried out by deCODE genetics applying the Centaurus (Nanogen) platform 38 . The c.2161C>T variant was genotyped using both Sanger sequencing and the Centaurus assay on a set of 351 individuals that had been enriched for carriers of c.2161C>T (82 heterozygotes but no homozygotes for c.2161C>T were observed). The two genotyping methods were consistent for all 351 individuals.
Sources of SNP imputations. SNPs were imputed based on published data from the HapMap2 European CEU sample 10 (60 triads) and the 1000 Genomes Project data 11 (179 individuals). Approximately 2.5 million SNPs were imputed based on the HapMap2 data, and 6.9 million SNPs were imputed based on the 1000 Genomes Project data. In addition, we genotyped Icelandic samples with the Illumina Human1M-Duo (123 triads) and the HumanOmni1-Quad chips (505 individuals) and then used these genotypes as the basis for imputing approximately one million SNPs from each chip into all the Icelandic samples genotyped with the smaller Illumina chips. SNPs showing substantial deviation from Hardy-Weinberg equilibrium were not imputed (P < 10 −7 ). A total of 7.2 million distinct SNPs were observed from the four imputation sources. When data for a SNP were available from multiple sources, we tested their association based on each source separately.
Whole-genome sequencing. This study includes whole-genome sequence data from 87 individuals, seven of whom were defined SSS cases. The other 80 individuals were selected from high-risk families with the following diseases: breast, prostate, ovarian or pancreatic cancers; schizophrenia; attention deficit disorder; Parkinson's disease; or multiple sclerosis. Sample preparation. Paired-end libraries for sequencing were prepared according to the manufacturer's instructions (Illumina). In short, approximately 5 µg of genomic DNA, isolated from frozen blood samples, was fragmented to a mean target size of 300 bp using a Covaris E210 instrument. The resulting fragmented DNA was end repaired using T4 and Klenow polymerases and T4 polynucleotide kinase with 10 mM dNTP followed by addition of an ' A' base at the ends using Klenow exo fragment (3′ to 5′-exo minus) and dATP (1 mM). Sequencing adaptors containing 'T' overhangs were ligated to the DNA products followed by agarose (2%) gel electrophoresis. Fragments of about 400 bp were isolated from the gels (QIAGEN Gel Extraction Kit), and the adaptor-modified DNA fragments were PCR enriched for ten cycles using Phusion DNA polymerase (Finnzymes Oy) and PCR primers PE 1.0 and PE 2.0 (Illumina). Enriched libraries were further purified using agarose (2%) gel electrophoresis as described above. The quality and concentration of the libraries were assessed with the Agilent 2100 Bioanalyzer using the DNA 1000 LabChip (Agilent). Barcoded libraries were stored at −20 °C. All steps in the workflow were monitored using an in-house laboratory information management system with barcode tracking of all samples and reagents.
DNA sequencing. Template DNA fragments were hybridized to the surface of flow cells (Illumina PE flowcell, v4) and amplified to form clusters using the Illumina cBot. In brief, DNA (8-10 pM) was denatured, followed by hybridization to grafted adaptors on the flowcell. Isothermal bridge amplification using Phusion polymerase was then followed by linearization of the bridged DNA, denaturation, blocking of 3 ends and hybridization of the sequencing primer. Sequencing-by-synthesis was performed on Illumina GAIIx instruments equipped with paired-end modules. Paired-end libraries were sequenced using 2 × 101 cycles of incorporation and imaging with Illumina sequencing kits, v4. Each library or sample was initially run on a single lane for validation followed by further sequencing of ≥4 lanes with targeted cluster densities of 250-300 k/mm 2 . Imaging and analysis of the data was performed using the SCS 2.6 and RTA 1.6 software packages from Illumina, respectively. Real-time analysis involved conversion of image data to base-calling in real-time.
Alignment. For each lane in the DNA sequencing output, the resulting qseq files were converted into fastq files using an in-house script. All output from sequencing was converted, and the Illumina quality filtering flag was retained in the output. The fastq files were then aligned against Build 36 of the human reference sequence using bwa version 0.5.7 39 .
BAM file generation. SAM file output from the alignment was converted into BAM format using samtools version 0.1.8 (ref. 40) , and an in-house script was used to carry the Illumina quality filter flag over to the BAM file. The BAM files for each sample were then merged into a single BAM file using samtools. Finally, Picard version 1.17 (see URLs) was used to mark duplicates in the resulting sample BAM files.
SNP calling and genotyping in whole-genome sequencing. A two-step approach was applied. The first step was to detect SNPs by identifying sequence positions where at least one individual could be determined to be different from the reference sequence with confidence (quality threshold of 20) based on the SNP calling feature of the pileup tool samtools 40 . SNPs that always differed heterozygous or homozygous from the reference were removed. The second step was to use the pileup tool to genotype the SNPs at the positions that were flagged as polymorphic. Because sequencing depth varies and hence the certainty of genotype calls also varies, genotype likelihoods rather than deterministic calls were calculated (see below). Of the 2.5 million SNPs reported in the HapMap2 CEU samples, 96.3% were observed in the whole-genome sequencing data. Of the 6.9 million SNPs reported in the 1000 Genomes Project data, 89.4% were observed in the whole-genome sequencing data.
Long range phasing. Long range phasing of all chip-genotyped individuals was performed with methods described previously 13, 41 . In brief, phasing is achieved using an iterative algorithm which phases a single proband at a time given the available phasing information about everyone else that shares a long haplotype identically by state with the proband. Given the large fraction of the Icelandic population that has been chip-typed, accurate long range phasing is available genome-wide for all chip-typed Icelanders.
Genotype imputation. We imputed the SNPs identified and genotyped through sequencing into all Icelanders who had been phased with long range phasing using the same model as used by IMPUTE 12 . The genotype data from sequencing can be ambiguous due to low sequencing coverage. In order to phase the sequencing genotypes, an iterative algorithm was applied for each SNP with alleles 0 and 1. We let H be the long range phased haplotypes of the sequenced individuals and applied the following algorithm: (i) For each haplotype h in H, use the Hidden Markov Model of IMPUTE to calculate for every other k in H, the likelihood, denoted γ h,k , of h having the same ancestral source as k at the SNP.
(ii) For every h in H, initialize the parameter θ h , which specifies how likely the one allele of the SNP is to occur on the background of h from the genotype likelihoods obtained from sequencing. The genotype likelihood L g is the probability of the observed sequencing data at the SNP for a given individual assuming g is the true genotype at the SNP. If respectively. (iv) Repeat step (iii) when the maximum difference between iterations is greater than a convergence threshold ε. We used ε=10 −7 .
Given the long range phased haplotypes and θ, the allele of the SNP on a new haplotype h not in H, is imputed as g q
The above algorithm can easily be extended to handle simple family structures such as parent-offspring pairs and triads by letting the P distribution run over all founder haplotypes in the family structure. The algorithm also extends trivially to the X-chromosome. If source genotype data are only ambiguous in phase, such as chip genotype data, then the algorithm is still applied, but all but one of the Ls will be 0. In some instances, the reference set was intentionally enriched for carriers of the minor allele of a rare SNP in order to improve imputation accuracy. In this case, expected allele counts will be biased toward the minor allele of the SNP. Call the enrichment of the minor allele E and let θ′ be the expected minor allele count calculated from the naïve imputation method, and let θ be the unbiased expected allele count, then′ = − + E E 1 and hence
This adjustment was applied to all imputations based on enriched imputations sets. We note that if θ′ is 0 or 1, then θ will also be 0 or 1, respectively. Association testing. Logistic regression was used to test for association between SNPs and disease, treating disease status as the response and expected genotype counts from imputation or allele counts from direct genotyping as covariates. Testing was performed using the likelihood ratio statistic. No additional covariates were used in the genome-wide association scan, but in an additional investigation of c.2161C>T, year of birth and year of birth squared were also used as covariates. The conditional analysis of the region around c.2161C>T was performed by adding the c.2161C>T variant as a covariate while testing every SNP in the region for association with SSS. Similarly, association with the quantitative ECG parameters was performed using linear regression, treating the ECG measurement as the response and the genotype as the covariate. Conditional analysis was performed by adding the allele count of the SNP being conditioned on as a covariate.
Sibling recurrence risk ratio. The sibling recurrence risk ratio is defined as ) log q where t is the age of the mutation in generations, θ is the recombination rate between the mutation and the SNP, x is the frequency of chromosomes carrying both the mutation and the SNP allele that has a higher frequency of the mutation on its background and y is the frequency of chromosomes carrying the mutation and the other SNP allele 15 where r is the rate of past exponential population growth, which we estimate as 0. 3 (ref. 42) . A single estimate for the age of the mutation in generations was then obtained by taking the geometric mean of the age estimates for each SNP, which was multiplied by 30 to obtain an estimate of the age of the mutation in years.
